|
Oct 3
|
Investors in Simulations Plus (NASDAQ:SLP) have unfortunately lost 26% over the last year
|
|
Oct 3
|
OptimizeRx (OPRX) Moves 5.4% Higher: Will This Strength Last?
|
|
Oct 1
|
Improve Demand Lifted Simulations Plus (SLP)
|
|
Jul 30
|
Simulations Plus Releases ADMET Predictor® Version 12
|
|
Jul 25
|
Simulations Plus to Participate in KeyBanc’s 25th Annual Technology Leadership Forum
|
|
Jun 25
|
Analysts Estimate Simulations Plus (SLP) to Report a Decline in Earnings: What to Look Out for
|
|
Jun 12
|
QHP Capital-Backed Pro-ficiency Acquired by Simulations Plus
|
|
Jun 12
|
Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum
|
|
Jun 4
|
Insider Sale: Director and 10% Owner Walter Woltosz Sells 20,000 Shares of Simulations Plus Inc ...
|
|
May 15
|
Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software
|
|
May 9
|
Director Daniel Weiner Sells 3,250 Shares of Simulations Plus Inc (SLP)
|
|
May 3
|
Insider Sale at Simulations Plus Inc (SLP): Director and 10% Owner Walter Woltosz Sells 20,000 ...
|
|
Apr 27
|
Simulations Plus' (NASDAQ:SLP) Returns On Capital Not Reflecting Well On The Business
|
|
Apr 12
|
New AI Bot Predicts These 7 Stocks Will Mint Millionaires
|
|
Apr 8
|
Simulations Plus (SLP) DILIsym Software Licenses Renewed by FDA
|
|
Apr 6
|
Earnings Update: Simulations Plus, Inc. Beat Earnings And Now Analysts Have New Forecasts For This Year
|
|
Apr 5
|
Simulations Plus Second Quarter 2024 Earnings: Beats Expectations
|
|
Apr 4
|
Simulations Plus, Inc. (NASDAQ:SLP) Q2 2024 Earnings Call Transcript
|
|
Apr 4
|
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
|
|
Apr 4
|
Simulations Plus (SLP) Q2 Earnings & Revenues Beat Estimates
|